Loading...

APC anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
MEL-14_APC_090707
C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • MEL-14_APC_090707
    C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Save
104411 25 µg ¥9,410
104412 100 µg ¥27,590
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Application References

(PubMed link indicates BioLegend citation)
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Cowan J, et al. 2013. J Exp Med. 210:675. PubMed
  2. Ender F, et al. 2017. PLoS One. 12(2):e0172446. PubMed
  3. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  4. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  5. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  6. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  7. Ferrao Blanco MN, et al. 2022. Br J Pharmacol. 179:2771. PubMed
  8. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  9. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  10. Hu X, et al. 2022. EBioMedicine. 86:104333. PubMed
  11. Dölz M, et al. 2022. iScience. 25:105372. PubMed
  12. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  13. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  14. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  15. Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed
  16. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  17. Chen F, et al. 2023. Acta Biomater. 164:387. PubMed
  18. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  19. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  20. Scieszka DP, et al. 2023. Respir Res. 24:138. PubMed
  21. Milighetti M, et al. 2023. iScience. 26:106937. PubMed
  22. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  23. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  24. Rezende R, et al. 2015. Nat Commun. 6: 8726. PubMed
  25. Wang J, et al. 2012. Blood. 120:1489. PubMed
  26. Martens R, et al. 2020. Nat Commun. 11:1114. PubMed
  27. Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed
  28. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  29. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  30. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  31. Gabriely G, et al. 2021. iScience. 24:103347. PubMed
  32. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  33. Shapiro MR, et al. 2020. Front Immunol. 1.972222222. PubMed
  34. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  35. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  36. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  37. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  38. Wei H, et al. 2021. Malar J. 20:89. PubMed
  39. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  40. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  41. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  42. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  43. Zhao Y, et al. 2021. J Biol Chem. 297:101166. PubMed
  44. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  45. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  46. Wiese A, et al. 2017. PLoS One. 10.1371/journal.pone.0184956. PubMed
  47. Roy S, et al. 2020. Sci Rep. 10:10992. PubMed
  48. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  49. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  50. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  51. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  52. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  53. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  54. Li Y, et al. 2020. Nat Commun. 11:2781. PubMed
  55. Parriott G, et al. 2020. Immunology. 160:280. PubMed
  56. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  57. Ma X et al. 2019. Cell Metab. 30(1):143-156 . PubMed
  58. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  59. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  60. Deng B, et al. 2022. J Immunother Cancer. 10:. PubMed
  61. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  62. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  63. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  64. Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed
  65. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  66. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  67. Kondratieva T, et al. 2020. PLoS One. 15:e0239668. PubMed
  68. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  69. Darragh LB, et al. 2022. Nat Commun. 13:7015. PubMed
  70. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  71. Fu X, et al. 2020. Aging (Albany NY). 12:15656. PubMed
  72. Yang W, et al. 2020. Methods Mol Biol. 2111:91. PubMed
  73. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  74. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  75. Coquery C, et al. 2014. PLoS One. 9:102284. PubMed
  76. Cowan J, et al. 2014. J Immunol. 193:1204. PubMed
  77. White C, et al. 2015. J Immunol. 194:697. PubMed
  78. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  79. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  80. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  81. Covarrubias AJ, et al. 2020. Nat Metab. 1265:2. PubMed
  82. Morimoto Y, et al. 2018. Immunity. 49:134. PubMed
  83. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
  84. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  85. Borges da Silva H, et al. 2020. Immunity. 53(1):158-171.e6. PubMed
  86. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  87. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  88. Ma K, et al. 2022. iScience. 25:104347. PubMed
  89. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  90. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  91. Jenkinson W, et al. 2012. PLoS One. 7:e53416. PubMed
  92. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  93. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  94. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  95. Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
  96. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  97. Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed
  98. Amezcua Vesely MC, et al. 2020. Cell. 178(5):1176-1188.e15.. PubMed
  99. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  100. Schaffert S, et al. 2015. J Immunol. 195: 1470-1479. PubMed
  101. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  102. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  103. Webb LM, et al. 2020. J Clin Invest. 130:1683. PubMed
  104. Shimba A et al. 2018. Immunity. 48(2):286-298 . PubMed
  105. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  106. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  107. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  108. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  109. Kooijman S, et al. 2015. Am J Physiol Heart Circ Physiol. 309: H646-H654. PubMed
  110. Lin JD, et al. 2020. Cell Host & Microbe. 27(5):830-840. PubMed
  111. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  112. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  113. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  114. Rochford I, et al. 2021. Am J Physiol Lung Cell Mol Physiol. 321:L686. PubMed
  115. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  116. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  117. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  118. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  119. Bae S, et al. 2021. Cell Reports. 35(11):109264. PubMed
  120. Louise V Webb et al. 2019. Immunity. 50(2):348-361 . PubMed
  121. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  122. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  123. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  124. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  125. Yu Z, et al. 2021. Biomed Res Int. 2021:9958745. PubMed
RRID
AB_313098 (BioLegend Cat. No. 104411)
AB_313098 (BioLegend Cat. No. 104412)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account